Effects of CROCUVIS+® on Computer Vision Syndrome, Sleep and Mood Disorders

University of Alicante100 enrolled

Overview

Previous research has shown the efficacy of CROCUVIS+® dietary supplement, based on saffron extract, in the proper functioning of visual health, for example, against the development of glaucoma. The main objective of this study is to evaluate the efficacy of CROCUVIS® in computer vision syndrome, sleep and mood disorders in a sample of university students who use digital devices.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

TRIPLE

Enrollment

100

Conditions

Computer Vision Syndrome Sleep Disorder Mood Disorders

Interventions

Saffron extract (Crocus sativus)DIETARY_SUPPLEMENT

Daily intake of one tablet for 42 days.

PlaceboDIETARY_SUPPLEMENT

Daily intake of one tablet for 42 days.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * CVS-Q© score ≥6. * Age between 18 and 40 years (both inclusive). * Exposure to digital devices 4 hours a day, at least five days a week or more and maintain the same level of exposure throughout the study period. Exclusion Criteria: * Monocular corrected distance visual acuity \>0.0 LogMAR. * Ocular pathology under treatment at the time of the study. * Previous ocular surgery that could affect the tear film or the ocular surface. * Ocular Surface Disease Index (OSDI) questionnaire score ≥13. * Previous diagnosis or history of dry eye syndrome and/or blepharitis. * Regular (daily) use of rigid or soft contact lenses ≥3 days a week. * Regular use of any ocular lubricant. * History of oral intake of dietary supplements, with or without herbal ingredients, intended to contribute, maintain or reduce the risk of suffering diseases related to visual function, mood or sleep within the four weeks before the study enrollment. * Systemic disease: 1. Uncontrolled hypertension (systolic/diastolic blood pressure \>140/90 mmHg). 2. Uncontrolled diabetes mellitus (fasting blood glucose level \>180 mg/dL). 3. Rheumatoid arthritis. 4. Tumor disease. 5. Active hepatitis (type B and C). 6. Active infectious disease. 7. Kidney disease that compromises diuresis. * Current systemic treatment or in the last 3 months with drugs that may interfere with the results, for example: 1. Opioids. 2. Antipsychotics. 3. Antibiotics (tetracyclines, sulfonamides) 4. Antiarthritic drugs (hydroxychloroquine) 5. Hypotensive drugs (beta-blockers) 6. Anticoagulants (heparin, warfarin, or clopidogrel) 7. Antidepressants (such as fluoxetine, among others) 8. Hypnotics (eg, benzodiazepines) * Habitual smoker and/or alcohol drinker. More than 3 cigarettes per day and/or more than 3 Standard Drink Units (SDU) per week, including weekends. SDU is defined as the consumption of 10 ml of alcohol. * Regular job with rotating shifts including night shift in the last month (including weekends). * Pregnancy or breastfeeding (also excludes recent pregnancy within the last 3 months) and women planning to become pregnant. * Participation in another clinical trial in the last 3 months. * Take any type of dietary supplements with botanical components in the last month.

Locations (1)

University of Alicante

San Vicent del Raspeig, Alicante, Spain

Outcomes

Primary Outcomes

Change from baseline computer vision syndrome at 14, 28 and 42 days

Measured with the Computer Vision Syndrome Questionnaire (CVS-Q©). It evaluates the frequency and intensity with which 16 symptoms are perceived over the time of use of digital devices. The score ranges from 0 to 32; computer vision syndrome is considered ≥6. The higher score a subject gained, the worsen ocular condition he/she experienced.

Time frame: 0 (baseline), 14, 28 and 42 days

Change from baseline sleep disorders at 14, 28 and 42 days

Measured with the Insomnia Severity Index (ISI). It evaluates 7 items. The score ranges from 0 to 28 (worst). Each item is evaluated on a 5-point Likert scale (from 0 to 4). The final score is obtained from the sum of the responses of all items; insomnia is considered ≥8.

Time frame: 0 (baseline), 14, 28 and 42 days

Change from baseline mood at 14, 28 and 42 days

Measured with the Profile of Mood States (POMS). It evaluates 58 items that form 6 factors (tension, depression, anger, vigour, fatigue, and confusion). The score ranges from 68 to 300 (worst mood). Each item is evaluated with a 5-point Likert scale (from 0 to 4). The score of each factor is obtained from the sum of the responses of all the items that define it. Total Mood Disturbance = 100+ (Tension + Depression + Anger + Fatigue + Confusion) - Vigour

Time frame: 0 (baseline), 14, 28 and 42 days

Secondary Outcomes

Change from baseline quality of life related to health at 42 days

Measured with Short Form-36 survey (SF-36). It evaluates 36 items that form 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, mental health). The scores are weighted sums of the questions in each section. The score ranges from 0 to 100. Lower scores = more disability, higher scores = less disability.

Time frame: 0 (baseline) and 42 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.